Quarterly report [Sections 13 or 15(d)]

Significant Accounting Policies - Additional Information (Detail)

v3.25.3
Significant Accounting Policies - Additional Information (Detail)
$ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Apr. 17, 2025
USD ($)
Apr. 30, 2025
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
Sep. 30, 2025
USD ($)
Product
Segment
Sep. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Subsidiary or Equity Method Investee [Line Items]                  
Credit card receivables     $ 70.5       $ 70.5   $ 53.1
Bad-debt expense     0.0 $ 0.0     0.1 $ 0.3  
Allowance for doubtful accounts     1.8       1.8   2.5
Allowances for product returns             $ 2.0   1.8
Number of geographic regions | Segment             5    
Number of product categories | Product             5    
Other operating income     0.0 5.0     $ 4.8 5.0  
Gain on extinguishment of debt             0.0 (10.5)  
Minority interest increase           $ 6.2      
Secretariat of the federal revenue bureau of brazil [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Restricted cash     15.2       15.2   $ 15.2
HBL Link Bioscience LLC [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Consideration to acquire assets   $ 6.5              
Ownership interest percentage   51.00%              
Link BioSciences Inc [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Cash paid   $ 6.5              
Asset acquisition contingent payments   0.0              
Reduction in cash   6.5              
Assets estimated fair value at the acquisition date   12.7              
Link BioSciences Inc [Member] | Goodwill [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Assets estimated fair value at the acquisition date   7.2              
Link BioSciences Inc [Member] | Software [Member] | Property Plant, and Equipment [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Assets estimated fair value at the acquisition date   2.5              
Link BioSciences Inc [Member] | Manufacturing Equipment [Member] | Property Plant, and Equipment [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Assets estimated fair value at the acquisition date   2.5              
Pruvit [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Consideration to acquire assets $ 19.0                
Pruvit [Member] | Developed Technology and Software [Member] | Property Plant, and Equipment [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Consideration to acquire assets 14.4                
Customer Relationships [Member] | Link BioSciences Inc [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Assets estimated fair value at the acquisition date   $ 0.5              
Customer Relationships [Member] | Pruvit [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Consideration to acquire assets 4.3                
Assembled Workforce [Member] | Pruvit [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Consideration to acquire assets 0.3                
Minimum [Member] | Contingent Milestone Payment Period [Member] | Pruvit [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Asset acquisition contingent payments 5.0                
Maximum [Member] | Contingent Milestone Payment Period [Member] | Pruvit [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Asset acquisition contingent payments $ 25.0                
Pro2col Health LLC [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Milestones period 10 years                
Additional payments $ 0.0                
Pro2col Health LLC [Member] | Contingent Milestone Payments Second [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Maximum milestone contingent payments 46.0                
Pro2col Health LLC [Member] | Minimum [Member] | Contingent Milestone Payments Third [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Contingent payments 5.0                
Pro2col Health LLC [Member] | Maximum [Member] | Contingent Milestone Payments First [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Contingent payments 2.0                
Pro2col Health LLC [Member] | Maximum [Member] | Contingent Milestone Payments Second [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Contingent payments 3.0                
Pro2col Health LLC [Member] | Maximum [Member] | Contingent Milestone Payments Third [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Contingent payments $ 15.0                
2018 Credit Facility [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Gain on extinguishment of debt         $ 2.5        
2018 Credit Facility [Member] | 2025 Senior Notes [Member] | Other (Income) Expense, Net [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Gain on extinguishment of debt               (10.5)  
China [Member]                  
Subsidiary or Equity Method Investee [Line Items]                  
Other operating income     $ 0.0 $ 5.0     $ 4.8 $ 5.0